Buoyed by recent investment from DSM, the CEO of Chromadex says the company is not scared to spend big to develop ingredients that stand up to increased scientific scrutiny and resonate with the market.
New ‘suspect alkaloids’ are finding their way into the controversial pre-workout supplement sector, and potentially dangerous products will continue to flourish in the marketplace while there is wider support from the industry, according to the CEO of Chromadex.
Natural products firm ChromaDex Corp. has entered into a material transfer agreement with Universite Libre de Bruxelles (ULB), under which ChromaDex will provide ULB with its recently launched Niagen nicotinamide riboside (NR).
Over 70% of Americans may be interested in reduced caffeine energy beverages that can offer the boost of caffeine but without the crash, according to a new survey conducted by Ipsos Research and commissioned by Chromadex.
Heads or tails, the yin and the yang – there are two sides to everything, and the same can be said for the ‘antioxidant’ debate. In this guest article, Steve Baugh, Technical Services Director of ChromaDex Analytics Inc, gives us his views on antioxidants and pro-oxidants, and the potential rise...
Daily supplements of pterostilbene may help reduce both systolic and diastolic blood pressure by over 7 mmHg, say findings presented at the American Heart Association's High Blood Pressure Research 2012 Scientific Sessions.
Cott Beverages Inc., and ChromaDex Inc. have entered into a licensing and supply agreement for the joint development of a proprietary ingredient blend combining the latter’s pterostilbene ingredient and the former’s grape extract.